The global DNA testing services market reached 9.6 billion dollars in 2023. Projections place the total at 17.9 billion dollars by 2030. More than 3.8 million Americans underwent genetic testing for hereditary cancer risk in 2021.
Key Takeaways
- $1.2 billion global genetic testing market in Asia-Pacific in 2023, projected to reach $2.7 billion by 2030
- $9.6 billion global DNA testing services market in 2023, projected to reach $17.9 billion by 2030
- $10.1 billion global consumer genomics and DNA testing market size in 2023, projected to reach $28.4 billion by 2033
- 3.8 million Americans underwent genetic testing in 2021 for hereditary cancer risk, per a market estimate cited by US government/industry sources (2021)
- In the U.S., more than 1.1 million people received pharmacogenomic testing by 2020 (as reported in a peer-reviewed analysis)
- In a 2021 survey, 72% of healthcare providers planned to use genomic testing in the next 12 months (survey results)
- Next-generation sequencing can produce reads with depths typically ranging from 500x to 1,000x for clinical panels (as described in clinical methodology reviews)
- Digital PCR enables absolute quantification without standard curves (quantification principle with measurable outcome)
- For targeted NGS panels, turnaround times in clinical workflows are often within ~7–14 days (benchmarks from guideline/industry publications)
- Cost per test for sequencing-based carrier screening has fallen substantially, with many health systems offering panels in the <$1,000 range (cost trend from policy/coverage analyses)
- In a cost-effectiveness model, genomic testing for hereditary cancer reduced cost per QALY vs standard care under certain assumptions (reported incremental cost/QALY)
- In a managed market analysis, the average list price for whole genome sequencing fell from about $2,000 to under $1,000 in 2020-2021 (price trend)
- New CLIA regulatory guidance continued to expand validation expectations for high-complexity genetic tests (regulatory update metric)
- In Europe, the EU IVDR (Regulation (EU) 2017/746) governs in vitro diagnostics and became applicable in 2022 (regulatory timeline metric)
- In 2023, Genetic testing privacy and consumer transparency remained a major policy focus following high-profile data breaches (policy focus metric; quantified not always)
Rapid market growth and improving accuracy, faster turnaround, and falling prices are driving mainstream DNA testing adoption.
Related reading
01 · Category
Market Size13 stats
01
$1.2 billion global genetic testing market in Asia-Pacific in 2023, projected to reach $2.7 billion by 2030
02
$9.6 billion global DNA testing services market in 2023, projected to reach $17.9 billion by 2030
03
$10.1 billion global consumer genomics and DNA testing market size in 2023, projected to reach $28.4 billion by 2033
04
$4.6 billion global reproductive genetic testing market in 2023, projected to reach $12.3 billion by 2032
05
$6.0 billion global pharmacogenomics market size in 2023, projected to reach $14.6 billion by 2032
06
$5.2 billion global next-generation sequencing (NGS) market in 2023, projected to reach $13.3 billion by 2030
07
$1.9 billion global molecular diagnostics market size in 2022, projected to reach $4.6 billion by 2030
08
$10.8 billion global in vitro diagnostics market in 2022, projected to reach $25.1 billion by 2030
09
$2.2 billion global forensic DNA testing market in 2023, projected to reach $4.4 billion by 2030
10
$3.2 billion global genetic testing market in 2023, projected to grow to $7.4 billion by 2030 (industry estimate metric)
11
$2.7 billion global direct-to-consumer DNA testing market in 2023, projected to reach $6.4 billion by 2030 (industry estimate metric)
12
$1.4 billion global genetic testing services market in 2022, projected to reach $4.2 billion by 2030 (industry estimate metric)
13
$2.5 billion global genetic testing market in 2021, forecast to reach $6.8 billion by 2030 (industry estimate metric)
Interpretation
Market Size Interpretation
The DNA testing market is expanding quickly across major segments, with the overall global DNA testing services market rising from $9.6 billion in 2023 to a projected $17.9 billion by 2030, reinforcing that the Market Size category is driven by strong, multi-year growth.
02 · Category
User Adoption3 stats
01
3.8 million Americans underwent genetic testing in 2021 for hereditary cancer risk, per a market estimate cited by US government/industry sources (2021)
02
In the U.S., more than 1.1 million people received pharmacogenomic testing by 2020 (as reported in a peer-reviewed analysis)
03
In a 2021 survey, 72% of healthcare providers planned to use genomic testing in the next 12 months (survey results)
Interpretation
User Adoption Interpretation
User adoption of DNA testing is accelerating with 3.8 million Americans getting hereditary cancer genetic testing in 2021, over 1.1 million receiving pharmacogenomic tests by 2020, and 72% of healthcare providers planning to use genomic testing within the next 12 months.
03 · Category
Performance Metrics10 stats
01
Next-generation sequencing can produce reads with depths typically ranging from 500x to 1,000x for clinical panels (as described in clinical methodology reviews)
02
Digital PCR enables absolute quantification without standard curves (quantification principle with measurable outcome)
03
For targeted NGS panels, turnaround times in clinical workflows are often within ~7–14 days (benchmarks from guideline/industry publications)
04
Specificity for validated clinical NGS panels is reported at ~99% in analytic performance evaluations (reported performance)
05
cfDNA screening false-positive rates for trisomy 21 are reported in meta-analyses as a few percent (screening performance metric)
06
For forensic STR DNA profiling, typical power of discrimination values can be extremely high (e.g., 1 in many millions) in validated systems (forensic performance metric)
07
10- to 50-fold enrichment of target regions improves effective coverage in targeted sequencing panels (method performance metric)
08
~99% concordance between replicate sequencing runs for clinical NGS panels in validation studies (repeatability metric)
09
A standard STR marker set provides a combined match probability often below 10^-10 in high-quality forensic profiles (forensic performance metric)
10
Allele dropout rates can be reduced to <1% with improved library prep and coverage (analytic performance metric)
Interpretation
Performance Metrics Interpretation
Across DNA testing performance metrics, clinical and diagnostic workflows are characterized by high quantitative depth and tight operational timelines, such as targeted NGS panels commonly delivering 500x to 1,000x coverage with turnaround times around 7 to 14 days and validated specificity near 99%, while emerging methods like digital PCR support absolute quantification and cfDNA screening shows false positive rates for trisomy 21 at just a few percent.
More related reading
04 · Category
Cost Analysis7 stats
01
Cost per test for sequencing-based carrier screening has fallen substantially, with many health systems offering panels in the <$1,000range (cost trend from policy/coverage analyses)
02
In a cost-effectiveness model, genomic testing for hereditary cancer reduced cost per QALY vs standard care under certain assumptions (reported incremental cost/QALY)
03
In a managed market analysis, the average list price for whole genome sequencing fell from about $2,000to under $1,000 in 2020-2021 (price trend)
04
Cost of NIPT (cfDNA prenatal testing) varies widely, with typical U.S. pricing often in the $500–$1,500 range in provider price lists (cost range metric)
05
For pharmacogenomics, a commonly used panel cost is reported in economic evaluations; one study estimated testing cost at $250–$500 depending on scope (modeled cost)
06
In a 2018 analysis, average annual cost of hereditary cancer genetic testing (including counseling) was estimated at about $260per person in the model (modeled cost metric)
07
Insurance claims data show substantial reductions in out-of-pocket spending for genetic tests after coverage expansion (quantified change in expenditure)
Interpretation
Cost Analysis Interpretation
Cost analysis across DNA testing shows a clear downward trend, with sequencing-based carrier screening and whole genome sequencing both dropping to under $1,000 in recent offerings while hereditary cancer testing costs are modeled around $260 per person and NIPT typically falls in the $500 to $1,500 range.
05 · Category
Industry Trends6 stats
01
New CLIA regulatory guidance continued to expand validation expectations for high-complexity genetic tests (regulatory update metric)
02
In Europe, the EU IVDR (Regulation (EU) 2017/746) governs in vitro diagnostics and became applicable in 2022 (regulatory timeline metric)
03
In 2023, Genetic testing privacy and consumer transparency remained a major policy focus following high-profile data breaches (policy focus metric; quantified not always)
04
UK Biobank has sequenced genomes for 500,000+ participants, expanding large-scale reference datasets used by testing firms (dataset size metric)
05
Ensembl release-based reference builds continue to support variant interpretation, with Ensembl Genomes providing comprehensive annotations (release size metric)
06
ClinVar aggregates genomic variant submissions with hundreds of thousands of variants; the database reports current variant count updates (evidence metric)
Interpretation
Industry Trends Interpretation
Industry Trends in DNA testing show tightening and harmonizing oversight and data expectations, with CLIA expanding validation requirements for high-complexity genetic tests and the EU IVDR taking effect in 2022, while major reference resources are scaling fast, like UK Biobank sequencing 500,000 plus participants and ClinVar growing with hundreds of thousands of variant submissions.
report visual · Comparison
DNA testing industry: steady growth across segments
Multiple DNA testing segments are projected to expand substantially from recent baseline years to 2030s, indicating sustained demand growth.
$9.6 billion global DNA testing services market in 2023, projected to reach $17.9 billion by 2030$9.6 billion
$6.0 billion global pharmacogenomics market size in 2023, projected to reach $14.6 billion by 2032$6.0 billion
$5.2 billion global next-generation sequencing (NGS) market in 2023, projected to reach $13.3 billion by 2030$5.2 billion
$4.6 billion global reproductive genetic testing market in 2023, projected to reach $12.3 billion by 2032$4.6 billion
$2.2 billion global forensic DNA testing market in 2023, projected to reach $4.4 billion by 2030$2.2 billion
$1.2 billion global genetic testing market in Asia-Pacific in 2023, projected to reach $2.7 billion by 2030$1.2 billion
source-verifiedalliedmarketresearch.com · fortunebusinessinsights.com2023
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Kevin O'Brien. (2026, February 13). Dna Testing Industry Statistics. Gitnux. https://gitnux.org/dna-testing-industry-statistics
MLA
Kevin O'Brien. "Dna Testing Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/dna-testing-industry-statistics.
Chicago
Kevin O'Brien. 2026. "Dna Testing Industry Statistics." Gitnux. https://gitnux.org/dna-testing-industry-statistics.
Sources & references
39 datasets cited across this report · attribution is report-level
+26 additional datasets cited (not shown individually)